NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

One would hope the FDA and other equivalent bodies would take the multiplicity inherent at this scale into account when judging approval. i.e the first in class trial has a lower bar to pass (say p<0.05) but for each subsequent combination the bar gets higher.

One would hope so, but I tend to agree with Longfellow on the idea that the FDA’s new stance with regard to oncology approvals is more of a giveaway to BP than out of concern for getting safe and effective drugs to patients faster. Sounds nasty, I agree, but that’s what I think is most likely. The latter is a cover for the former.

Hope I come to find I’m wrong on that ultimately! Since cancer strikes one out of two males, we’re both looking down the barrel of a loaded gun. It is in our interest to understand where truth resides in the hall of mirrors that surrounds cancer treatments.

BTW, I think it would be instructive to look at how the multiplicity issue plays out across the thousands of ICI trials in progress. Don’t know where to begin on something of that truly ginormous size but it’d be a great project for some enterprising grad student to tackle — could make quite a name for him/herself.

Unfortunately, depending on the findings, it could well be a career-limiting move.

The following was no doubt intended as a warning to such enterprising researchers. The highly respected co-founder of the evidence-based medicine group Cochrane Collaboration was just fired because he followed the evidence were it led. The repression of science/medical evidence is not ancient history:

Gøtzsche speculated that some foundations funding the collaboration had pressured it to get rid of him because of his highly critical views about pharma.

https://www.sciencemag.org/news/2018/09/evidence-based-medicine-group-turmoil-after-expulsion-co-founder?r3f_986

Hmmm...foundations, Pharma. Might be worth looking into that connection. Anyway, back to the Gøtzsche affair:

In a letter giving his side of the story, Gotzsche argued that the Cochrane Collaboration is pursuing a business model to the detriment of scientific independence. Evidence-based medicine is at enormous risk of manipulation by commercial parties, unwittingly aided by practitioners, professional bodies and patient groups, although I (author of article) suspect that some beneficiaries know what they’re doing.

https://www.independent.co.uk/life-style/health-and-families/cochrane-collaboration-medical-research-protest-peter-gotzsche-antidepressants-drugs-a8552581.html%3famp


Very worth reading up on. Google “Gøtzsche fired” to explore in more depth, fellow truth seekers.